Hougaard etal.  in this issue of the Scandinavian Journal of Pain report on a randomised, double blind, placebo controlled cross-over study in the aura phase of migraine from which we can learn a great deal about trial design and generalisability of trial results.NXN-188 is an oral dual action nNOS-inhibitor and 5HT1B/1D receptor agonist. A total of 50 patients were randomised between two different sequences of NXN-188 and placebo. However, only 18 patients completed the trial and were available for the planned analysis. No statistically significant difference between NXN-188 and placebo was demonstrated. As stated by the authors, the low number of patients completing the study prevents a firm conclusion on lack of efficacy. Nevertheless, the results presented do not seem very promising.The authors have experienced large problems recruiting patients to the trial and have faced an unexpectedly high propor-tion of drop-outs before the second treatment period. Probably they would have been hesitant to initiate this trial had they known that the final statistical analysis would include only 18 completers. The figure illustrating patient disposition illustrates their challenge. Out of 615 patients contacted by telephone 563 did not meet entry criteria or did not wish to participate in the
Scandinavian Journal of Pain – de Gruyter
Published: Jan 1, 2013
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera